Flushing clinical trials
The registry lists 22 studies for Flushing across more than 10 countries. 5 are recruiting or about to start. 12 of them are mainly about Flushing (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.
Get an email when these change. Save the Flushing studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Merck Sharp & Dohme LLC (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Biogen (1) · Assaf-Harofeh Medical Center (1) · Eastern Virginia Medical School (1) · Radboud University Medical Center (1) · University of Bologna (1) · University of Pennsylvania (1)
What is being tested here
Drugs under test in Flushing studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Aspirin | 0 | 0 | 2 |
| Lanreotide | 0 | 1 | 1 |
| Brimonidine | 0 | 0 | 1 |
| Psyllium | 0 | 0 | 1 |
| Quercetin | 0 | 0 | 1 |
| Octreotide | 0 | 0 | 1 |
Who these studies take
Of the 4 Flushing studies recruiting now, 4 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 1 (25%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 4 (100%) | 3 (75%) |
| 30 | 4 (100%) | 3 (75%) |
| 40 | 4 (100%) | 3 (75%) |
| 50 | 4 (100%) | 3 (75%) |
| 65 | 4 (100%) | 3 (75%) |
| 75 | 4 (100%) | 3 (75%) |
| 85 | 4 (100%) | 3 (75%) |
Across all 22 studies, recruiting or not: 32% stop at 75 or younger and 9% at 65; 9% take children; 14% are for women only and 5% for men only; 32% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 22 of 22. search them.
- ALDH2 Genetic Testing in East Asian CommunityNot yet recruitingNCT07392775Not applicable1 country
- Transcutaneous Auricular Vagus Nerve Stimulation Treatment for RosaceaRecruitingNCT07600424Not applicable1 country
- A Standard Carbon Dioxide Flushing Protocol to Reduce Air Embolization During Thoracic Endovascular Aortic RepairRecruitingNCT07734584Not applicable1 country
- Pulsatile Flushing Technique in Reducing Blockage of T-CVAD for Haemodialysis PatientsRecruitingNCT07567456Not applicable1 country
- Influence of Iyengar Yoga on the Bio-functional Age of Postmenopausal WomenRecruitingNCT04705623Not applicable1 country
- Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With RosaceaCompletedNCT06582043Not applicable2 countries
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid SyndromeCompletedNCT00774930Phase 311 countries
- Clinical Pharmacology of Platinum-based Hyperthermic Intraperitoneal ChemotherapyCompletedNCT033649071 country
- Efficacy of Uterine Lidocaine Flushing in HyFoSyStatus unknownNCT04433611Not applicable1 country
- Treatment of Asian Flushing Syndrome With Topical Alpha AgonistsCompletedNCT03497442Early Phase 11 country
- Effects of Psyllium on Niacin TolerabilityCompletedNCT03370848Phase 41 country
- Endpoint Validation Study (0524A-015)CompletedNCT00533676Phase 2
- Effect of MK0524A on Flushing Caused by Niacin (0524A-056)CompletedNCT00533611Phase 3
- Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT02090413Phase 42 countries
- MK0524A Phase IIb Study (0524A-011)(COMPLETED)CompletedNCT00536237Phase 2
- Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)CompletedNCT00913081Phase 41 country
- P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid SyndromeTerminatedNCT01886287Phase 21 country
- Alternative Options to Minimize Niacin-Induced FlushingCompletedNCT00895193Not applicable1 country
- Effects of PRK 124 Lotion in Acne RosaceaCompletedNCT00580723Phase 1/21 country
- A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy VolunteersCompletedNCT00608699Phase 11 country
- Role of Prostaglandins on Niacin-Induced FlushingCompletedNCT009308391 country
- Blood Factors in Mastocytosis and Unexplained Anaphylaxis and FlushingCompletedNCT000479181 country